Pfizer/BioNTech COVID-19 vaccine, bivalent – Authorized as booster dose in 6 months – 4 years of age
March 14, 2023 - The FDA amended the emergency use authorization (EUA) of the Pfizer/BioNTech COVID-19 vaccine, bivalent to provide for a single booster dose of the vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the monovalent (single strain) Pfizer/BioNTech COVID-19 vaccine.
Top